Drug Trial Radar · NCT00865969
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Dec 15, 2008
Primary completion
Nov 5, 2013
Study completion Oct 27, 2014
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Valerio Therapeutics
- First posted
- Mar 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.
Conditions
- Peripheral T-cell Lymphoma
Interventions
BelinostatDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: 24 months
Locations
117 sites in 17 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Wilshire Oncology Medical Group, Inc
La Verne, California
Comprehensive Cancer Center
Palm Springs, California
Yale Cancer Center-Section of Medical Oncology
New Haven, Connecticut
Oncology Associates of Bridgeport
Trumbull, Connecticut
Boca Raton Clinical Research Associates
Boca Raton, Florida
Georgia Health Sciences University
Augusta, Georgia
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Kellogg Cancer Care Center
Evanston, Illinois
Illinois Cancer Specialists/Cancer Care & Hematology Specialists of Chicagoland
Niles, Illinois
Illinois CancerCare, P.C.
Peoria, Illinois
Center for Cancers and Blood Disorders
Bethesda, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Saint Louis University
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Northern New Jersey Cancer Associates
Hackensack, New Jersey
Morristown Memorial Hospital
Morristown, New Jersey
Erie County Medical Center (Roswell Park)
Buffalo, New York
Monter Cancer Center
Lake Success, New York
New York University Cancer Institute
New York, New York
New York University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Upstate Medical Univeristy Syracuse
Syracuse, New York
Bronx River Medical Associates, PC
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
Hematology Associates
Bedford, Ohio
St Luke's Cancer Center
Bethlehem, Pennsylvania
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Avera Cancer Center
Sioux Falls, South Dakota
Associates In Oncology and Hematology
Chattanooga, Tennessee
University of Tennessee Cancer Institute
Knoxville, Tennessee
Accelerated Community Oncology Reseaerch Network, Inc. (ACORN)
Memphis, Tennessee
UT - M. D. Anderson Cancer Center
Houston, Texas
The UT Health Science Centre at San Antonio
San Antonio, Texas
Massey Cancer Center
Richmond, Virginia
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.